

- Atherosclerosis (*Cont.*):
 lipoprotein disorders and, 2435. *See also*
 Lipoprotein disorders
 pathogenesis of, **291e-1**
 atheroma evolution in, 291e-1f, 291e-2-3
 foam-cell formation in, 291e-2
 initiation of, 291e-1-2, 291e-1f
 leukocyte recruitment in, 291e-2
 microvessel formation in, 291e-3
 plaque formation in, 291e-3, 292e-1v,
 1579
 plaque instability and rupture in, 291e-3f,
 291e-4, 291e-5f, 292e-1v, 1579, 1599.
See also Myocardial infarction (MI)
 plaque stabilization in, 291e-3f, 292e-1v
 peripheral. *See* Peripheral artery disease
 prevention of, 291e-8t, 291e-9, 291e-9f
 renal, 1835t, 1847. *See also* Renovascular
 disease
 risk factors for, 291e-6t, 2569
 assessment of, 291e-9-10
 diabetes mellitus, 291e-6-7
 dysregulated coagulation and fibrinolysis,
 291e-8-9
 gender, 291e-7-8
 hypertension, 291e-6
 inflammation, 291e-9, 291e-9f
 lipid disorders, 291e-4-6, 291e-7t
 postmenopausal state, 291e-7-8
- Atherothrombosis, 291e-3
- Athetosis, 2619t
- Athlete(s)
 androgen abuse in. *See* Anabolic-androgenic
 steroid (AAS) abuse
 concussion in, 457e-4
 sudden cardiac death in, 1767
- Atlastin* gene, 2634t, 2636
- ATM (ataxia-telangiectasia mutated), 102e-2
- ATM gene mutations
 actions of, 102e-2, 102e-2f, 434
 in ataxia-telangiectasia, 101e-6t, 434, 451e-3t,
 2630
 breast cancer risk and, 101e-6t
 pancreatic cancer risk and, 554
 in T-cell prolymphocytic leukemia, 135e-3
- ATN (acute tubular necrosis). *See* Acute kidney
 injury (AKI)
- ATNAA (Antidote Treatment Nerve Agent
 Autoinjector), 262e-6, 262e-6f
- Atomic bomb survivors, 678
- Atomoxetine, 2644
- Atonic seizures, 2543-2544
- Atopic dermatitis, **344**
 allergic contact dermatitis and, 345
 asthma and, 1669-1670
 clinical features of, 344t, 354t, 2119
 in children, 344
 distribution of skin lesions, 341t, 342f, 344,
 354t
 in infants, 344
 lichenification and scaling, 76e-1f, 344f
 morphology of skin lesions, 341t, 354t
 pruritus, 344
 diagnosis of, 354t
 differential diagnosis of, 2119
 erythroderma, 344t
 etiology of, 344
 genetic considerations in, 344
 immunopathology of, 372e-24t
 inflammatory mediators in, 372e-29t
 treatment of, 344-345, 354t, 391
- Atopobium vaginae*, 874
- Atopy, 1669-1670, 2114
- Atorvastatin, 42, 42t, 2218t, 2447, 2448t
- Atovaquone
 action of, 246e-7
 adverse effects of, 246e-2t, 1380t
 for *Babesia* infection, 780t, 1386, 1386t
 drug interactions of, 246e-2t
 for malaria, 1380t
 for malaria prophylaxis, 1382, 1383, 1383t
 for PCB, 1361t
 for PCP prophylaxis, 1251t, 1362t
 pharmacology of, 246e-7-8, 1380t
 in pregnancy and lactation, 246e-2t
 for toxoplasmosis prophylaxis in HIV
 infection, 1251t
- ATP1A1* gene mutations, 306, 2589
- ATP2B3* gene mutations, 306
- ATP7B* gene mutations, 367e-2, 2519
- ATP8B1* gene mutations, 284
- ATP III (National Cholesterol Education Project
 Adult Treatment Panel III), 480e-3t
- ATRA. *See* All-trans-retinoic acid (ATRA)
- Atrax robustus*, 2748
- Atresia
 biliary, 2068, 2083
 esophageal, 1904
- Atrial fibrillation (AF), **1485**
 clinical features of, 1485-1486
 CT pulmonary valve mapping in, 271e-10f
 early onset, 436t
 ECG in, 278e-9f, 278e-10f, 278e-11f, 1487f
 epidemiology of, 1486
 in heart failure, 1514
 in hypertrophic cardiomyopathy, 1570
 mechanism of, 273e-2, 273e-3t
 in mitral stenosis, 1539
 palpitations in, 254
 paroxysmal, 1486, 1486f
 persistent, 1486, 1486f
 preexcited, 1482, 1483f
 in pulmonary edema, 1763
 risk factors for, 1486
 in SA node dysfunction, 1468
 stroke and, 1485t, 1488, 2564, 2567t, 2570
 syncope in, 1487, 1487f
 in thyrotoxicosis, 2294
 treatment of, **1487**
 cardioversion and anticoagulation, 1487
 catheter and surgical ablation, 1488-1489
 rate control, 1487-1488
 rhythm control, 1488-1489
 stroke prevention, 1485t, 1488, 2566t
- Atrial flutter
 common right, 1484, 1484f
 ECG in, 278e-8f, 278e-9f, 1484f
 treatment of, 1484
 vs. tremor artifact, 278e-5f
- Atrial natriuretic peptide (ANP)
 action of, 332e-6f, 332e-9
 in edema, 251
 in hyporeninemic hypoaldosteronism, 310
 in lung cancer, 511
- Atrial septal defect (ASD), **1520**
 AV conduction block in, 1472
 clinical features of, 297e-9, 1520-1521
 complications of, 1521
 diagnosis of
 cardiac catheterization, 1463
 ECG, 269e-11f, 1521
 echocardiography, 270e-25, 270e-25f, 297e-
 7f, 297e-8f, 1521, 1522f
 heart sounds/murmur, 51e-1, 51e-3-4, 51e-
 6, 1447f, 1448, 1521
 physical examination, 1521
 differential diagnosis of, 1521
 locations of, 297e-7f, 1521f
 vs. mitral stenosis, 1540
 ostium primum, 51e-4, 297e-7f, 1472, 1520
 ostium secundum, 51e-4, 297e-7f, 1520
 sinus venosus, 51e-4, 1520
 treatment of, 296e-4, 297e-7-9, 297e-7f, 297e-
 8f, 297e-9v, 1521
- Atrial tachycardia (AT)
 ECG in, 278e-5f, 278e-6f, 278e-7f, 1479f
 focal, 1477, 1478f, 1479, 1479f
 macroreentrant, 1485-1486
 mechanism of, 273e-3
 multifocal, 278e-5f, 1485, 1486f
 treatment of, 1485
- Atriofascicular pathways, 1481
- Atrioventricular (AV) bundle, 1470-1471
- Atrioventricular (AV) conduction block, **1471**
 in cardiac mesothelioma, 289e-2
 CMR in, 270e-22f, 271e-7f
 complete, 1471, 1472
 congenital, 1471t, 1472
 diagnosis of, 1473-1474
 electrophysiology of, 1472-1473
 epidemiology of, 1466
 etiology of, 1471-1472, 1471t
 first-degree, 269e-6f, 269e-16f, 1472-1473,
 1472f
 high-grade, 1473, 1473f, 1474f
 iatrogenic, 1472
 in Lyme disease, 278e-4f, 1151, 1472
 mechanism of, 273e-3t
 in myocardial infarction, 1609
 paroxysmal, 1473, 1473f
 second-degree, 278e-2f, 278e-3f, 278e-4f,
 1472-1473, 1472f
 treatment of, 1474-1476, 1475t, 1476t
- Atrioventricular (AV) nodal reentry tachycardia,
 278e-7f, 1478f, 1479-1480, 1481f
- Atrioventricular (AV) node, 273e-1, 1466,
 1470-1471
- Atrioventricular (AV) reentry tachycardia, 1478f,
 1481
- Atrophie blanche (livedoid vasculopathy), 369,
 369t, 1651
- Atrophie blanche en plaque, 1649. *See also*
 Livedo reticularis
- Atrophy, muscle, 462e-3-4
- Atropine
 adverse effects of, 254
 for AV conduction block, 1473, 1474
 for bradycardia, 1770
 for ciguatera poisoning, 2742
 for nerve agent exposure, 262e-5t, 262e-6,
 262e-6f, 473e-10t
 overdose/poisoning with, 473e-8t
 for SA node dysfunction, 1469
 for snakebite treatment, 2737t
- ATRX* gene mutations, 2354t
- ATRX* pathway, 632-633, 638
- Attention, assessment of, 168
- Attentional deficit, 183
- ATTR amyloidosis, 720t, 723-724. *See also*
 Amyloidosis
- Atypical adenomatous hyperplasia, 515
- Atypical chronic myeloid leukemia (aCML),
 135e-5-6, 135e-5t
- Atypical hemolytic uremic syndrome (aHUS),
 657, 730, 1832
- Atypical lipomatous tumor, 119e-1. *See also* Soft
 tissue sarcoma
- AUA Symptom Index, 587t
- AUC/MIC, 935, 935f
- Audiogram, 222
- Audiometry, 221-222
- AUDIT (Alcohol Use Disorder Screening Test),
 2727, 2727t
- AUDIT-C (Alcohol Use Disorders Identification
 Test-Consumption), 471e-5t
- Auditory brainstem responses, 223
- Auditory cortex, 176f
- Auditory nerve, 217
- Auer rod, 81e-9f, 681, 682f
- Aura, 2543, 2589
- Auricular cellulitis, 228
- Auricular chondritis, 2203, 2204f
- Auscultation
 abdominal, 286
 cardiac. *See* Heart murmurs; Heart sounds
 pulmonary, 47e-3, 1662
- Austin Flint murmur, 51e-6, 1449, 1537, 1540
- Australian bat lyssaviruses, 1304
- Australian blue-ringed octopus envenomation,
 2740
- Australian jellyfish sting, 2739
- Autism spectrum disorders, 444e-1, 444e-6,
 465e-1, 465e-2t
- Autoantibody(ies)
 autoantigens and, 372e-24-25t
 blood group, 138e-1
 drug-induced, 44
 in inflammatory myopathies, 219e
 islet cells, 2404
 pathogenicity of, 377e-3t, 377e-4
 in SLE, 377e-5, 2125, 2126t, 2131
- Autocrine regulation/signaling, 102e-3, 400e-6